Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

Cancer

Volumn 116, Issue 15, 2010, Pages 3663-3669

  Hainsworth, John D ^a,b   Ervin, Thomas ^c   Friedman, Elke ^d   Priego, Victor ^a   Murphy, Patrick B ^b   Clark, Bobby L ^a   Lamar, Ruth E ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Virginia Cancer Institute ^*

^d Center for Cancer and Blood Disorders   (United States)

Author keywords

Antiangiogenesis agents; Combined modality; First line; Glioblastoma multiforme; Sorafenib; Temozolomide

Indexed keywords

SORAFENIB; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PYRIDINES;

EID: 77955363593     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25275     Document Type: Article

References (22)

1. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991;64:769-774.
2. Levin V, Leibel S, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997: 2022-2086.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
4. Maxwell M, Naber SP, Wolfe HJ, et al. Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res. 1991;51:1345-1351.
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729. (Pubitemid 350086473)
6. Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas [abstract]. J Clin Oncol. 2008;26:94s. Abstract 2021.
7. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112:2267-2273.
8. Nghiemphu P, Graham C, Liu W, et al. A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma [abstract]. J Clin Oncol. 2008;26:95s. Abstract 2023.
9. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol. 2008;26:91s. Abstract 2010b.
10. Mohile NA, Abrey LE, Lymberis SC, Karimi S, Hou BL, Gutin PH. A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas [abstract]. J Clin Oncol. 2007;25:82s. Abstract 2028.
11. Lai A, Nghiemphu P, Green R, et al. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme [abstract]. J Clin Oncol. 2009;27:87s. Abstract 2000.
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125-134. (Pubitemid 46089673)
14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27:4155-4161.
17. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27:3861-3867.
18. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579-584.
19. Steinke W. BAY43-9006: quantitative whole body autoradiography. Distribution of radioactivity and elimination from blood, organs and tissues after single oral administration to male Wistar rats and pigmented Long Evans rats of [14C]BAY54-9085 (tosylate salt of [14C]BAY43-9006). Study No. I8001548. Report No. PH-32654. Internal Archive. 2003.
20. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23: 5892-5899. (Pubitemid 46300205)
21. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double- blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/ leucovorin and PTK787/ZK 222584 or placebo (CONFIRM- 1) [abstract]. J Clin Oncol. 2005;23:2s. Abstract LBA3.
22. Gruber ML, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity [abstract]. J Clin Oncol. 2009;27:91s. Abstract 2017.